A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Study ID
NCT02795988

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Active, not recruiting

Trial Acronym

Trial Summary

The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131. The RP2D will be evaluated in the dose expansion Phase 2 study. The Phase 2 study is a randomized, open label comparison of IMU-131 plus standard of care chemotherapy versus standard of care chemotherapy alone.

More informations

Trial Starting Date

Aug 30,2017

Requirements

Gender All
Minimum age 20 Years
Maximum age N/A

Enrollement Limit